New York, New York holds a crowded market for peptide injections. Clinics in Manhattan advertise BPC-157, semaglutide, and other compounds, and several rank high in local search results. Patients in the five boroughs face dozens of options, from Upper East Side practices to telehealth sites that ship from out of state. Rankings measure ad spend. They say nothing about the license behind the prescription.
One step matters before payment. Ask which provider writes the prescription. Then check that provider in the New York state license lookup, the public database for physicians and nurse practitioners. A lapsed or restricted license appears there, along with any discipline on record.
Ask which pharmacy compounds the peptide. A 503A or 503B pharmacy registers with the FDA, and federal law requires a prescription before that pharmacy dispenses. Ask what the evaluation includes and the total monthly cost. Then pay.
The compounding pharmacy question
Most peptides sold as treatment lack FDA approval as finished drugs. A pharmacy that makes them works under federal rules that split into two tracks.
503A. A state-licensed pharmacy compounds for an identified patient. A prescriber writes a prescription first, then the pharmacy fills it. The pharmacist works from a patient-specific order. State boards of pharmacy license these operations, and the state inspects them. Making a batch before a prescription arrives falls outside this track.
503B. An outsourcing facility registers with the FDA and makes larger batches, often without a patient-specific prescription on file. It follows federal current good manufacturing practice and faces FDA inspection on a set schedule. Clinics and hospitals buy from these facilities when they need volume.
The FDA keeps a Category 2 list of substances it considers unsuitable for compounding. Safety concerns drive some entries. The availability of a commercial version drives others. A pharmacy that compounds a Category 2 substance raises a fair question about its sourcing.
Then there is the ingredient itself. A compounding pharmacy buys its raw peptide from a supplier. The supplier should hold FDA registration and provide a certificate of analysis. A label tells you little about potency or purity. Ask the pharmacy where its ingredient comes from and whether it tests each lot.
Ask which pharmacy fills the prescription. Ask whether it holds a 503A license or a 503B registration. Then look it up. State boards of pharmacy publish license lookups, and New York licenses pharmacies through the State Education Department. The FDA publishes its 503B facility list and its Category 2 list. Compare the pharmacy name against both before money changes hands.
Questions that separate clinics
Can the clinic name the prescriber and share a license number?
Ask for the full name and the license type, such as MD, DO, or NP. A patient can check that license in the state Board of Medicine or Board of Nursing public lookup. In New York, confirm the license status before a prescription.
Does the clinic name the compounding pharmacy and its 503A or 503B status?
Ask which federal path the pharmacy follows. A 503A pharmacist compounds for a specific patient with a prescription, while a 503B facility operator registers with the FDA. Ask for the pharmacy name, then check its license and any FDA warnings.
Does the initial evaluation include a history, labs, and a discussion of risks?
Ask whether a licensed prescriber reviews the patient's history, current medications, and prior peptide use. Ask whether the clinic orders baseline labs and who reviews the results. A brief online form with no review falls short.
Can the clinic describe its response if a patient has a reaction?
Ask who answers after hours and how the clinic documents the event. Ask whether the prescriber stops the peptide and reports the reaction to the FDA MedWatch program. A clear plan matters.
Does the clinic quote a total cost each month that includes consultation, medication, and follow-up?
Ask for the price of the initial visit, the peptide, shipping, and each follow-up. Ask whether the clinic charges for dose changes or lab work. A low medication price can hide fees elsewhere.
What New York clinics get right and wrong
New York hosts two shapes of telehealth peptide practice, and the differences matter for a patient.
The first shape is the franchise men's-health model. A corporate parent runs the brand across several cities. Intake moves fast, often through a short online form. The parent sets the protocol and the price. Speed and consistency count as the selling point. A patient in New York gets the same script as a patient in Dallas. Ask who employs the prescriber and which pharmacy compounds the drug. A franchise answers to its corporate owner.
The second shape is the physician-owned practice. One prescriber, or a small group, holds a New York license and sees patients with a longer intake. That visit includes history and a conversation about goals. The pace feels slower because one clinician carries the caseload. Accountability lands on the prescriber, whose license a state medical board can suspend over a bad call.
Both shapes can get the easy parts right: a clean website and a clear price. Both can get the hard parts wrong: a rushed intake, a vague answer about the compounding pharmacy, a refusal to name the supervising physician.
A patient can verify either model. Look up the prescriber in the state medical board's public license lookup. Ask which pharmacy compounds the peptide and whether that pharmacy holds a 503A or 503B registration. Ask whether the FDA places the drug on its Category 2 list, which bars routine compounding. Ask what the monthly total covers, including the medication and the lab fees.
Federal law requires a prescription before any dispensing.
Red flags
Payment before evaluation. A clinic asks for a card before a clinician reviews your history. Federal law requires a prescription before a pharmacy dispenses a compounded peptide. A payment-first page reverses that order. Ask what the evaluation includes and who performs it.
Guaranteed outcomes. A clinic that promises a result ignores uncertainty. The FDA has not approved compounded peptide products for any use. Ask for the approval status of the exact peptide. That detail matters.
No verifiable practice address. A real practice lists a street address. In New York City, a post office box alone fails this test. Check the prescriber's license in the state Board of Medicine or Board of Nursing public lookup. Ask for the clinician's name.
Urgency pressure. Limited-time pricing and same-day deadlines push a decision. A legitimate evaluation allows time to review risks and alternatives. A countdown timer favors the seller.
Refusal to name the pharmacy. Compounded drugs come from a 503A or 503B pharmacy. Ask which one and in which state it holds a license. A vague answer blocks a check of the FDA Category 2 list.
What a legitimate New York clinic looks like
A legitimate clinic hands over paperwork at the first visit. A patient should leave with four items.
The prescriber's name and license number. Ask for both, then check the number in the New York state public license lookup. Credentials differ: a physician and a nurse practitioner hold separate licenses with separate scopes.
The compounding pharmacy. Ask which pharmacy fills the prescription and where it operates. A 503A pharmacy compounds under state law against a patient-specific prescription. A 503B facility registers with the FDA. Ask which applies.
A written plan with costs. The plan lists the drug, the dose, the refill schedule, and the monthly total. Federal law requires a prescription before dispensing. The FDA has placed several compounded peptides on its Category 2 list, a sign the agency questions their safety or effectiveness.
A contact for problems. The patient needs a phone number or portal that reaches a clinician. Ask who answers at night.
A clinic that stalls on any of these items gives the patient a reason to look elsewhere.